Galapagos to present promising findings in cystic fibrosis programs at NACFC 2015
October 08 2015 - 1:37AM
Galapagos NV (Euronext & NASDAQ: GLPG) is present with a
strong delegation presenting or contributing to five posters at
the North American Cystic Fibrosis Conference (NACFC) in
Phoenix this week.
Thursday, 8 October 11.50 AM - 1.50 PM MST All posters
Friday, 9 October 7.30 AM - 8.45 AM Poster 50
Potentiators: how do they impact the fate of CFTR during
biogenesis? Insights are presented on the contribution of
GLPG1837 to the rescue of F508del CFTR
Poster 70 Insight into the mechanisms of correctors and
potentiators Galapagos and Abbvie developed new tools to better
understand the mechanism of action of correctors and potentiators
in its CF portfolio
Poster 62 Using BLISS analysis to categorize
corrector-corrector interactions Galapagos and AbbVie disclose
the usage of a modelling tool to categorize interactions between
candidate corrector compounds in their CF program
Poster 258 Safety, tolerability and pharmacokinetics of a
novel CFTR Potentiator GLPG1837 in healthy volunteers Galapagos
presents safety and tolerability of GLPG1837 in healthy human
volunteers, paving the path for the Phase 2 study in Class III
mutation patients to start by end 2015. More information on
this poster will be published later during the conference.
Saturday, 10 October 7.30 AM - 8.45 AM Poster 219 Novel
Potentiators Augment Efficacy of Translational Readthrough in CFTR
Nonsense Mutations Promising pre-clinical data using Galapagos
potentiators on Class I (nonsense) CFTR mutations is presented
These posters will be made available on the Galapagos website,
www.glpg.com, shortly following the presentation sessions.
The North American Cystic Fibrosis Conference is sponsored by
the Cystic Fibrosis Foundation: www.cff.org
About cystic fibrosis (CF) CF is a rare,
life-threatening, genetic disease that affects approximately 80,000
patients worldwide and approximately 30,000 patients in the United
States. CF is a chronic disease that affects the lungs and
digestive system. CF patients, with significantly impaired
quality of life, have an average lifespan approximately 50% shorter
than the population average, with the median age of death at
27. There currently is no cure for CF. CF patients
require lifelong treatment with multiple daily medications,
frequent hospitalizations and ultimately lung transplant, which is
life-extending but not curative. CF is caused by a mutation
in the gene for the CFTR protein, which results in abnormal
transport of chloride across cell membranes. Transport of
chloride is required for effective hydration of epithelial surfaces
in many organs of the body. Normal CFTR channel moves
chloride ions to outside of the cell. Mutant CFTR channel
does not move chloride ions, causing sticky mucous to build up on
the outside of the cell. CFTR dysfunction results in
dehydration of dependent epithelial surfaces, leading to damage of
the affected tissues and subsequent disease, such as lung disease,
malabsorption in the intestinal tract and pancreatic
insufficiency.
About Galapagos Galapagos (Euronext &
NASDAQ: GLPG) is a clinical-stage biotechnology company specialized
in the discovery and development of small molecule medicines with
novel modes of action, with a pipeline comprising three Phase 2
programs, two Phase 1 trials, five pre-clinical studies, and 20
discovery small-molecule and antibody programs in cystic fibrosis,
inflammation, and other indications. Filgotinib is an
orally-available, selective inhibitor of JAK1 for the treatment of
rheumatoid arthritis and potentially other inflammatory diseases.
Galapagos has reported good activity and a favorable safety profile
in both the DARWIN 1 and 2 trials in RA. Galapagos is
preparing to enter Phase 3 studies in RA and to report Phase 2
topline results with filgotinib in Phase 2 in Crohn's disease. In
the field of cystic fibrosis, AbbVie and Galapagos signed a
collaboration agreement to develop and commercialize molecules that
address mutations in the CFTR gene. Potentiator GLPG1837 has
completed a Phase 1 trial, and corrector GLPG2222 is expected
to enter Phase 1 by end 2015. GLPG1205, a first-in-class inhibitor
of GPR84 and fully-owned by Galapagos, will report topline results
in Q4 2015 from a Phase 2 proof-of-concept trial in
ulcerative colitis patients. GLPG1690, a fully proprietary,
first-in-class inhibitor of autotaxin, has shown favorable safety
in a Phase 1 trial and is expected to enter Phase 2 in idiopathic
pulmonary fibrosis. The Galapagos Group, including fee-for-service
subsidiary Fidelta, has approximately 400 employees, operating from
its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. More info at www.glpg.com
CONTACT
Galapagos NV
Investors: Elizabeth Goodwin, VP IR &
Corporate Communications Cell: +1 781 460 1784
Media inquiries: Evelyn Fox, Director Communications Tel: +31 6
53 591 999
ir@glpg.com
Galapagos forward-looking statements This release may
contain forward-looking statements, including statements regarding
the promising findings demonstrated in the Company's product
candidates for cystic fibrosis. Galapagos cautions the reader
that forward-looking statements are not guarantees of future
performance. Forward-looking statements involve known and
unknown risks, uncertainties and other factors which might cause
the actual results, financial condition and liquidity, performance
or achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions
and liquidity, performance or achievements expressed or implied by
such forward-looking statements. In addition, even if
Galapagos' results, performance, financial condition and liquidity,
and the development of the industry in which it operates are
consistent with such forward-looking statements, they may not be
predictive of results or developments in future periods.
Among the factors that may result in differences are the inherent
uncertainties associated with competitive developments, clinical
trial and product development activities and regulatory approval
requirements (including that data from Galapagos' ongoing clinical
research programs in cystic fibrosis may not support registration
or further development of potentiators and/or correctors due to
safety, efficacy or other reasons), Galapagos' reliance on
collaborations with third parties (including its collaboration
partner, AbbVie, who may not devote sufficient resources to the
development and commercialization of the cystic fibrosis programs),
and estimating the commercial potential of our product
candidates. A further list and description of these risks,
uncertainties and other risks can be found in the company's
Securities and Exchange Commission filing and reports, including in
the company's prospectus filed with the SEC on May 14, 2015 and
future filings and reports filed by the company with the Securities
and Exchange Commission. Given these uncertainties, the
reader is advised not to place any undue reliance on such
forward-looking statements. These forward-looking statements
speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change
in its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based or
that may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements, unless
specifically required by law or regulation.
HUG#1957556
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024